Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by JonesTrading

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by equities researchers at JonesTrading from a “hold” rating to a “buy” rating in a report released on Wednesday, MarketBeat Ratings reports. The brokerage currently has a $29.00 price target on the stock. JonesTrading’s price objective would indicate a potential upside of 120.53% from the company’s current price.

A number of other research analysts also recently commented on NTLA. Wells Fargo & Company boosted their price target on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Tuesday. Chardan Capital reissued a “buy” rating and issued a $26.00 target price on shares of Intellia Therapeutics in a report on Friday, February 27th. Evercore set a $8.00 target price on shares of Intellia Therapeutics and gave the company an “in-line” rating in a research report on Tuesday, November 11th. Oppenheimer set a $27.00 price target on shares of Intellia Therapeutics in a research report on Friday, November 7th. Finally, Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 18th. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $19.59.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $13.15 on Wednesday. The business’s 50 day simple moving average is $12.25 and its 200 day simple moving average is $13.10. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.25. The company has a market capitalization of $1.55 billion, a P/E ratio of -3.43 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.27) EPS. On average, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 53,051 shares of company stock valued at $488,600 in the last quarter. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. Contrarius Group Holdings Ltd boosted its stake in shares of Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after buying an additional 2,288,146 shares during the period. Vanguard Group Inc. raised its holdings in Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after buying an additional 1,965,181 shares during the last quarter. State Street Corp boosted its position in Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after buying an additional 1,447,967 shares during the period. Finally, Jupiter Asset Management Ltd. bought a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $23,519,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.